Compare Google Inc (GOOG) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Google Inc vs Sanofi SA — how do they compare? Google Inc trades at $341.36 (market cap $4.20T), while Sanofi SA trades at $43.6 (market cap $104.30B). The key difference: Google Inc is far larger — about 40.3× Sanofi SA's market cap, and Sanofi SA pays the higher dividend (5.55%). Which is the better fit depends on your goals.
| GOOG | SNY | |
|---|---|---|
Market Cap | $4.20T | $104.30B |
Volume | 1,511,127 | — |
Sector | Technology | Health |
52-Week High | $399.06 | $52.34 |
52-Week Low | $200.19 | $41.33 |
Enterprise Value | $4.09T | $124.19B |
Dividend Yield | 0.26% | 5.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Alphabet (GOOG) trades at $342.71, down 3.69% on the day, with technical indicators showing a bearish trend near support at $340. The company reported strong fundamentals with Q2 2026 EPS of $9.11 beating expectations, revenue growth to $402.84B in 2025, and robust profitability margins. Recent news highlights AI advancements, including Gemini reaching 1 billion users, but also regulatory scrutiny from French media.
The stock presents a compelling long-term opportunity with a consensus price target of $431.67, representing 26% upside, supported by 87% analyst buy ratings. Risks include high capital expenditure forecasts up to $205B for 2026, competitive AI pressures, and ongoing regulatory challenges. Investors should weigh strong cash flow generation against aggressive investment cycles.
SNY trades at $43.62, up 0.32% today, with a neutral technical signal and bullish moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21 versus $1.10 expected, and raised its 2026 outlook. Revenue for 2025 was $46.72B with net income of $7.81B, showing improved profitability. Analyst consensus is mixed with 44% Buy, 52% Hold, and 4% Sell ratings. Recent news highlights regulatory approvals for new drugs and pipeline developments under new CEO leadership.
The outlook for SNY is cautiously optimistic, driven by Dupixent's growth and new drug approvals, but faces risks from pipeline setbacks and competition. Earnings momentum and cost discipline support upside potential, though valuation multiples like a P/E of 23.27 may limit near-term gains. Key risks include biosimilar threats post-2031 and ongoing legal challenges. Institutional activity shows increased holdings, reflecting confidence in the company's strategic direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Google Inc
Alphabet Inc. operates as a holding company. The Company, through its subsidiaries, provides web-based search, advertisements, maps, software applications, mobile operating systems, consumer content, enterprise solutions, commerce, and hardware products.
Read more on GOOG →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
